Cargando…

PD-L1 pathway as a novel target in carcinosarcoma of the kidney and renal pelvis

Carcinosarcoma of the kidney and renal pelvis (CSKP) is a rare and highly-aggressive malignancy characterized by rapid progression and widespread metastases. To date, few studies describe the natural history of the disease. We present a patient placed on pembrolizumab therapy for suspected metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Raghavan, Ashwin M., Giffen, Zane C., Irwin, Patrick M., Mostafa, Hesham I., Buck, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260670/
https://www.ncbi.nlm.nih.gov/pubmed/32489894
http://dx.doi.org/10.1016/j.eucr.2020.101261
Descripción
Sumario:Carcinosarcoma of the kidney and renal pelvis (CSKP) is a rare and highly-aggressive malignancy characterized by rapid progression and widespread metastases. To date, few studies describe the natural history of the disease. We present a patient placed on pembrolizumab therapy for suspected metastatic colon cancer. The patient was found to have a right renal mass with caval extension on surveillance and ultimately underwent radical surgery revealing carcinosarcoma with positive PD-L1 expression with no evidence of recurrence to date. To our knowledge, this is the first case describing PD-L1 expression in CSKP and presents a novel pathway for future treatment algorithms.